Replies to post #300056 on Anavex Life Sciences Corp (AVXL)

[Jonjones325]

Thanks. Is this a phase 2 trial? They are saying "Study" and using "We"

Also seems like a very quick study. Let's see if it goes where it needs to.

Then proceed to the next step.

[plexrec]

TTT-"Evaluation of ANAVEX2-73 (blarcamesine) in Participants "--great find--thank you !!!!

[makemydaze]

Thanks for the find Triple T - It's great to see the MJFF make these statements -

"In 132 patients with Parkinson’s disease dementia, the drug significantly improved cognitive function and memory as well as REM sleep. This includes complex cognitive tasks that impact quality of life such as making a choice between similar objects and remembering daily personal experiences, which could be impaired in Parkinson’s disease. In patients with Alzheimer’s disease a Phase 2a trial demonstrated a concentration dependent response in both cognition (MMSE) and function (ADCS-ADL) over 148 weeks (longer than 3 years)."

https://www.michaeljfox.org/grant/evaluation-anavex2-73-blarcamesine-participants-parkinsons-disease

[Bourbon_on_my_cornflakes]

Anavex 273 WORKS: In 132 patients with Parkinson’s disease dementia, the drug significantly improved cognitive function and memory as well as REM sleep. This includes complex cognitive tasks that impact quality of life such as making a choice between similar objects and remembering daily personal experiences, which could be impaired in Parkinson’s disease. In patients with Alzheimer’s disease a Phase 2a trial demonstrated a concentration dependent response in both cognition (MMSE) and function (ADCS-ADL) over 148 weeks (longer than 3 years).

What other drug has shown significant IMPROVEMENT in PDD patients?

[Investor2014]

Thanks for this find TTT.

Interesting with the high focus on whether "ANAVEX2-73 (blarcamesine) can safely travel through the body to the final destination in parts of the brain most affected by Parkinson’s disease, which will help us determine if this new drug can help people with Parkinson’s disease".

We know A2-73 does reach the mouse brain with S1R occupancy vs. dose seemingly linear until a plateau.

We know that high contraction of A2-73 is key to efficacy, but we puzzle with why it seems dose vs. concentration is not a linear function in humans.

This small study seem clearly aimed at figuring that out before embarking on, dare I say, a pivotal P3.